To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Persistent heterogeneity … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective

Journal article
Authors Z. Sumnik
A. Szypowska
V. Iotova
N. Bratina
V. Cherubini
Gun Forsander
S. Jali
J. F. Raposo
G. Stipančic
A. Vazeou
H. Veeze
K. Lange
N. Papo
D. Kownatka
S. Lion
P. Gerhardsson
T. Kalina
B. Rami-Merhar
J. Svensson
R. Hanas
M. Knip
M. Witsch
R. Verkauskiene
S. Todorovic
P. Toth-Heyn
M. Ng
J. Pelicand
K. Podolakova
B. Timar
K. Casteels
R. Cordona Hernandez
H. Hoey
Published in Pediatric Diabetes
Volume 20
Issue 4
Pages 434-443
ISSN 1399-543X
Publication year 2019
Published at Institute of Clinical Sciences, Department of Pediatrics
Pages 434-443
Language en
Keywords children, diabetes technology, reimbursement, type 1 diabetes
Subject categories Diabetology, Pediatrics


Background: Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. Methods: The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. Results: We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. Conclusions: Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement. © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?